What are the recommended treatment options for osteopenia, including calcium and vitamin D supplementation, lifestyle measures, and pharmacotherapy such as bisphosphonates or denosumab?

Osteopenia Treatment

For osteopenia (T-score between -1.0 and -2.5), optimize calcium intake to 1,000-1,200 mg/day and vitamin D to 600-800 IU/day, combined with lifestyle modifications including weight-bearing exercise, smoking cessation, and limiting alcohol to 1-2 drinks daily—pharmacologic therapy with bisphosphonates should only be added if fracture risk assessment indicates moderate-to-high risk.

Risk Stratification is Critical

The approach to osteopenia hinges entirely on fracture risk assessment, not just the T-score alone. The evidence consistently shows that low-risk patients should not receive pharmacologic therapy beyond calcium and vitamin D 1, 2.

For Low-Risk Patients (Most Osteopenia Cases)

• Calcium supplementation: 1,000-1,200 mg/day 1, 2, 1
• Vitamin D supplementation: 600-800 IU/day (target serum level ≥20 ng/mL) 1, 2, 1
• Weight-bearing or resistance training exercise regularly 1
• Maintain healthy body weight 1
• Smoking cessation 1
• Limit alcohol to 1-2 beverages/day 1
• Balanced diet 1

Do not prescribe bisphosphonates, denosumab, or other pharmacologic agents for low-risk osteopenia—the guidelines provide a conditional recommendation for calcium and vitamin D over these medications due to low-quality evidence of additional benefit, costs, and potential harms 1.

For High-Risk Osteopenia (Age ≥65 with Additional Risk Factors)

Use the FRAX tool to calculate 10-year fracture risk. Pharmacologic treatment should be considered if:

• 10-year risk of major osteoporotic fracture ≥20%, OR
• 10-year risk of hip fracture ≥3% 2

Additional risk factors warranting assessment include:

• History of fragility fracture
• Weight <127 lb (58 kg)
• Parental history of hip fracture
• Current smoking
• Medications causing bone loss (especially glucocorticoids)
• Diseases causing bone loss 2

Pharmacologic Therapy Algorithm (When Indicated)

First-Line: Oral Bisphosphonates

Preferred agents based on safety, cost, and proven efficacy 1, 2, 3:

• Alendronate: 10 mg daily or 70 mg weekly
• Risedronate: 5 mg daily or 35 mg weekly

These are preferred due to strong evidence for fracture reduction, favorable safety profile, and lower cost compared to alternatives 1, 3.

Second-Line Options (If Bisphosphonates Inappropriate)

In order of preference 1:

1. IV bisphosphonates (zoledronic acid 5 mg annually)

   • Use if concerns about absorption or adherence with oral formulations
   • Higher risk profile than oral bisphosphonates 1

2. Raloxifene (60 mg daily) for postmenopausal women

   • Reduces vertebral fractures but NOT hip fractures
   • Consider in younger postmenopausal women 2, 3
   • Avoid if: history of venous thromboembolism, stroke risk, or immobility 2

3. Denosumab (60 mg subcutaneously every 6 months) 4

   • Effective for fracture reduction 5, 6
   • Critical caveat: Rapid bone loss upon discontinuation—requires transition to bisphosphonate 4, 6
   • More expensive than bisphosphonates 1

Anabolic Agents (Reserve for Severe Cases)

Teriparatide or romosozumab should be reserved for:

• Very high fracture risk
• Failed bisphosphonate therapy
• Severe osteoporosis (T-score ≤-3.0) with fractures 1, 7, 6

These are NOT first-line for osteopenia due to cost, burden of daily injections, and lack of evidence in lower-risk populations 1, 8.

Treatment Duration and Monitoring

• Duration: 5 years for bisphosphonates 3
• Monitoring: Routine BMD monitoring during treatment is NOT recommended 3
• Reassessment: Clinical fracture risk reassessment annually 1

Common Pitfalls to Avoid

1. Over-treating low-risk osteopenia: Most patients with osteopenia do NOT need pharmacologic therapy—calcium, vitamin D, and lifestyle modifications are sufficient 1, 9

2. Stopping denosumab abruptly: This causes rapid bone loss and rebound vertebral fractures—always transition to bisphosphonate if discontinuing 4, 6

3. Using estrogen therapy: The 2017 ACP guidelines provide a strong recommendation against menopausal hormone therapy for osteoporosis due to increased cardiovascular and breast cancer risks 3

4. Ignoring vitamin D levels: Ensure serum 25-OH vitamin D ≥20 ng/mL before starting any pharmacologic therapy to prevent severe hypocalcemia, especially with denosumab 1, 4

5. Treating based solely on T-score: Always incorporate clinical risk factors and FRAX assessment—the T-score alone is insufficient 2, 3